Abciximab

Revision as of 19:17, 29 January 2014 by Gerald Chi (talk | contribs) (Changed protection level for "Abciximab" ([Edit=Allow only autoconfirmed users] (expires 19:17, 12 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 19:17, 12 February 2014 (UTC))))
Jump to navigation Jump to search

Synonyms: 7E3 antibody, ReoPro, abciximab, c7E3

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Dosing and Administration

The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10-60 minutes before the start of PCI, followed by a continuous intravenous infusion of 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours.

Patients with unstable angina not responding to conventional medical therapy and who are planned to undergo PCI within 24 hours may be treated with an Abciximab 0.25 mg/kg intravenous bolus followed by an 18- to 24-hour intravenous infusion of 10 µg/min, concluding one hour after the PCI.

Indications

Contraindications

Side effects

Drug interactions

Precautions

Instructions for administration

Pharmacokinetics

How supplied

Patient information

FDA package label

Detailed information

Official website

Adapted from the FDA Package Insert.